JAMA Network
About The Study: In this study, adolescents with obesity prescribed a glucagon-like peptide 1 receptor agonists (GLP1R) had a lower incidence of suicidal ideation or attempts compared with matched patients not prescribed GLP1R who were treated with lifestyle intervention. These results suggest a favorable psychiatric safety profile of GLP1R in adolescents. The detected reduction in hazard ratios for suicidal ideation among adolescents with obesity prescribed GLP1R suggests potential avenues for future research.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
